Direct answer. A heart transplant replaces a severely diseased heart with a donor heart. A ventricular assist device, often an LVAD, mechanically supports circulation while the original heart remains. These are specialist options for selected people with advanced heart failure; they have different eligibility, risks and long-term responsibilities. Transplantation requires ongoing rejection prevention and surveillance, while a durable pump requires device-specific care and emergency preparation. Confidence is high in these distinctions; this guide attributes clinical education rather than independently ranking devices or promising survival. NHSBT heart-transplant overview and BTS collaboration; clinical date unclosed; NHLBI selected VAD framework, March24,2022; dated device wording.
- Transplantation and an LVAD are different treatments, sometimes used in sequence.
- Assessment considers the whole person, including other organs and practical support.
- A transplant waiting list matches donor organs; it does not guarantee a date.
- A donor heart needs ongoing rejection prevention even when someone feels well.
- Pump care, alarms, clotting and bleeding require a plan from the specialist team.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Who may be assessed? | Specialist clinical education | Selected advanced heart failure; no single online measurement decides eligibility. |
| Is an LVAD a donor-heart replacement? | Device definition | No. It assists circulation; a total artificial heart is another category. |
| Does listing guarantee a transplant? | UK allocation education | No. Matching, health changes and organ availability affect the pathway. |
| Does feeling well rule out rejection? | Surveillance education | No. Planned tests may detect problems before symptoms. |
| Does institution branding establish device independence? | Financial source boundary | No. Original device and drug trials need separate financial screening. |
Confidence is high in the transplant-versus-pump distinctions and need for specialist assessment; eligibility, prognosis and a monitoring plan require the treating team. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
Donor-heart transplantation, LVADs and artificial hearts
Advanced heart failure can make everyday activity difficult and lead to serious deterioration despite other care. A transplant assessment asks whether replacing the heart could offer a worthwhile balance of benefit and risk. It does not mean that every person with heart failure should undergo transplantation. NHSBT heart-transplant overview and BTS collaboration; clinical date unclosed.
An LVAD assists the left ventricle, the main chamber sending blood to the body. Mechanical support can be considered while waiting for transplantation, while assessing recovery or suitability, or as longer-term treatment in selected circumstances. The intended purpose should be stated clearly rather than inferred from the device name. NHLBI selected VAD framework, March24,2022; dated device wording.
A total artificial heart replaces the pumping ventricles and associated valves rather than assisting the existing left ventricle. It is a different specialist approach. The cited2023 source is used for that distinction, not as a complete current approval or access list. NHLBI total artificial heart definition, April12,2023; dated approval menu excluded.
Whole-person assessment and donor compatibility
Assessment considers heart function and severity alongside kidney and lung health, infection, cancer history, other illnesses and the ability to manage ongoing treatment. The question is whether the proposed treatment fits the whole situation. A low ejection fraction alone cannot settle this. NHSBT selected transplant assessment tests; clinical date unclosed.
Tests may examine cardiac structure, rhythm, blood flow and pressures, exercise capacity, lung function and donor compatibility. Blood group and antibodies can matter for matching. Not every person needs the same test sequence, and an article cannot interpret results into a place on a transplant list. NHSBT selected transplant assessment tests; clinical date unclosed.
Some conditions make surgery or the subsequent treatment too risky. Others may improve enough for reassessment. NHSBT describes selected mechanical-support pathways for people whose suitability could change. Ask what is reversible, what remains uncertain and when the team will review the decision. NHSBT reasons transplantation may not suit; clinical date unclosed.
Discuss help with transport, medicines and daily care early. Difficulty arranging support is a practical problem to address with the team, not a reason to hide concerns. Assessment and consent should include what life after treatment may involve. NHSBT selected hospital recovery and discharge planning; clinical date unclosed.
Specialist options, listing and donor offers
The advanced-heart-failure team can discuss ongoing medical care, transplantation and mechanical support according to the diagnosis, stability and goals. Being referred or assessed is not the same as being listed, and listing is not the same as receiving an organ. NHSBT reasons transplantation may not suit; clinical date unclosed.
In the UK, the waiting list is a matching system rather than a simple first-come queue. Listed patients need to remain contactable and tell the team about illness, admissions and changed contact details. Other countries have their own allocation systems; UK processes should not be assumed universal. NHSBT waiting-list and matching explanation; clinical date unclosed.
A donor offer involves trade-offs. Screening reduces but cannot eliminate the possibility of transmitting an infection or other disease, and donor characteristics can affect the assessment. The team should explain any unusual donor concerns and the alternatives to accepting that offer. NHSBT donated-heart risk discussion; clinical date unclosed.
Ask which symptoms or clinical outcomes a proposed pump or transplant is intended to improve, which risks are most relevant and what happens if the first plan fails. This guide does not supply a comparative device ranking or financially independent survival estimate: complete original trial sponsorship and author chains were not cleared.
Supportive care and decisions about comfort, burdens and goals can remain important throughout the pathway. Ask for discussion of the options if transplantation or mechanical support does not fit the situation, rather than treating the assessment result as the end of care. NHSBT reasons transplantation may not suit; clinical date unclosed.
Recovery, prevention care and supplement limits
After transplant, diet, appropriate activity and smoking support can form part of ongoing care. The plan should fit recovery, other illnesses and medicine effects. Ask about rehabilitation and restrictions before resuming demanding activity; a general recovery timetable is not personal exercise clearance. NHSBT selected ongoing lifestyle and prevention context; clinical date unclosed.
Immunosuppression makes infection prevention and food safety especially relevant. The team should provide current guidance appropriate to the person and local setting. This article does not give a universal food-ban list, vaccine schedule or permission to use live vaccines. NHSBT selected ongoing lifestyle and prevention context; clinical date unclosed.
No independently screened supplement regimen is established here to replace a transplant medicine, prevent rejection or keep an LVAD free from clots. A changed laboratory marker or an “immune health” label does not demonstrate a safe transplant outcome.
Discuss every nonprescription and herbal product before taking it. The NHSBT recovery source explicitly warns that such products can affect immunosuppressants. Bring the actual ingredients rather than assuming a familiar brand has an unchanged formula. NHSBT selected care at home after transplantation; clinical date unclosed.
Rejection surveillance and device preparation
A transplanted heart can be attacked by the recipient’s immune system. Immunosuppressive medicines reduce that risk but do not eliminate it. Feeling stronger or having no obvious symptoms does not show that these medicines are unnecessary. NHSBT rejection explanation and surveillance; clinical date unclosed.
Follow-up may include blood tests, imaging and assessment for rejection; the exact surveillance plan varies. Tests can detect a problem before the person feels ill. Ask what a particular result means and who will communicate any treatment changes. NHSBT rejection explanation and surveillance; clinical date unclosed.
An implanted pump involves a controller and power supply, and some systems have a driveline passing through the skin. Before going home, the patient and support network need device-specific preparation. Training should cover the actual system, contact routes and arrangements when equipment or power is unavailable. Royal Papworth actual24-page LVAD patient guide, March2025 version1.
Patient stories can help formulate questions but cannot establish a controlled treatment effect or predict an individual outcome.
Transplant complications, pump risks and urgent warnings
Transplant surgery and early recovery can involve serious complications. Hospital care may include intensive monitoring and temporary support. Discharge depends on recovery and readiness to manage care, rather than the passage of a fixed number of days. NHSBT selected hospital recovery and discharge planning; clinical date unclosed.
Rejection and infection need continuing attention. Longer-term concerns include kidney problems, high blood pressure, diabetes, bone health and some cancers. Risks differ across people and over time; an undated average percentage is not used here as a personal prediction. NHSBT selected long-term complication context; clinical date unclosed.
Cardiac allograft vasculopathy is disease of the donor heart’s coronary blood vessels, involving immune effects and other factors. It may produce few symptoms until advanced, so follow-up matters. Assessment and treatment are led by the transplant team; this guide gives no automatic stent or repeat-transplant rule. NHSBT cardiac allograft vasculopathy explanation; clinical date unclosed.
Mechanical support can cause infection, bleeding, clotting, device malfunction and problems in the unsupported part of the heart. The team needs to explain the relevant device’s risks and its plan for medicines and monitoring. An LVAD does not remove every cause of cardiac deterioration. NHLBI selected VAD framework, March24,2022; dated device wording.
After transplant, contact the team promptly about fever or shivering, new breathlessness, significant vomiting or diarrhoea, severe headache or marked deterioration. Do not wait for a particular temperature if seriously unwell. For severe chest pain, breathing difficulty, collapse or stroke symptoms, use local emergency services. NHSBT transplant warning signs; clinical date unclosed.
Medicine interactions and procedure coordination
Transplant medicines can have important interactions, and some require blood-level monitoring. Every service involved should know the current prescription. Before another clinician starts an antibiotic or changes treatment, make clear that the person has a transplant and how to reach the specialist team. NHSBT selected transplant-medicine roles and cautions; clinical date unclosed.
Over-the-counter and herbal products are part of the same review. Ask before adding them and tell the team about accidental changes, missed medicine or difficulty keeping doses down. Do not treat a vomiting episode as permission to improvise repeat doses. NHSBT selected care at home after transplantation; clinical date unclosed.
For a pump, the anticoagulation plan balances clotting and bleeding risks. Confirm who manages it and how other procedures will be coordinated. This guide gives no blood-test target, interruption schedule or instruction to add aspirin. Royal Papworth actual24-page LVAD patient guide, March2025 version1.
Keep hospital, primary-care and pharmacy records consistent so a new prescription can be checked against the complete regimen.
Suitability changes, family planning and children
Transplantation is unsuitable for some people because the overall risks are excessive or expected benefit is inadequate. Frailty, infection, cancer, other-organ disease and the practical burden of lifelong care can affect discussion. These are individualized assessments, not a self-administered exclusion checklist. NHSBT reasons transplantation may not suit; clinical date unclosed.
Temporary illness can change whether a person is active on a waiting list; a lasting change may require reassessment. Tell the team promptly and ask what the status means. Do not assume that suspension is either a permanent rejection or a guarantee of later surgery. NHSBT waiting-list and matching explanation; clinical date unclosed.
Pregnancy, breastfeeding and family planning require specialist review of the actual transplant medicines and cardiac situation. Some medicines can have substantial reproductive risks. This guide does not import the source’s dated fathering-related switch wording or provide permission to stop immunosuppression. NHSBT selected transplant-medicine roles and cautions; clinical date unclosed.
An adult treatment page does not establish the right pathway for a child. Paediatric anatomy, device choices and transplant assessment require the child’s specialist service. Ask the team to explain the relevant options rather than copying adult eligibility or recovery expectations. NHSBT selected transplant assessment tests; clinical date unclosed.
Written plans, training and ongoing support
There is no personal medicine dose, pump setting or alarm troubleshooting procedure here. Use the written instructions for the actual transplant regimen or device and confirm the contact route available outside routine hours. Device emergencies require the trained specialist response, not an online generic controller-change sequence. Royal Papworth actual24-page LVAD patient guide, March2025 version1.
Transplant prescriptions and tests may change with results, side effects and recovery. Clarify who authorizes a change and how it will be communicated. A lower dose at one stage does not mean that eventual stopping is expected. NHSBT selected transplant-medicine roles and cautions; clinical date unclosed.
Before discharge, discuss supplies, wound care, medicine access, home help and follow-up. Ask the team to check understanding with the support network. Unclear instructions should be resolved before they become a missed prescription or a device-care problem. NHSBT selected hospital recovery and discharge planning; clinical date unclosed.
Report new symptoms, admissions and difficulty following the plan. Ask for practical and emotional support when needed. NHSBT waiting-list and matching explanation; clinical date unclosed.
Laboratory findings versus clinical transplant outcomes
Laboratory and animal research can help explain immune injury or device engineering, but cannot determine human transplant eligibility, a safe immunosuppressant dose or a device’s clinical benefit. Engineering performance, animal outcomes and patient survival are different endpoints. No animal or in-vitro finding supplies this guide’s independent clinical verdict.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 21 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Donor organs have no corporate owner. Commercial pump, diagnostic and immunosuppressant businesses have revenue interests. NHSBT own audited accounts and Bristol contact were checked separately from national NHS finances. Its BTS collaboration has relevant officially indexed corporate-sponsor routes with full direct-access gaps. Original drug/device trials, individual contributor ties and exact page allocations remain unclosed; manufacturer-origin efficacy is excluded.
The clinical indication is separate from the ownership of commercial device products. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHSBT heart-transplant overview and BTS collaboration; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Transplant definition and explicitly stated BTS clinical partnership. |
| NHSBT selected transplant assessment tests; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Selected whole-person and compatibility assessment. |
| NHSBT reasons transplantation may not suit; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Suitability, reassessment and advanced-care alternatives. |
| NHSBT waiting-list and matching explanation; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: UK matching, contact and ongoing review; fixed timings excluded. |
| NHSBT donated-heart risk discussion; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Specific donor-risk consent and residual screening uncertainty. |
| NHSBT selected hospital recovery and discharge planning; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Critical-care recovery, discharge and support preparation. |
| NHSBT selected care at home after transplantation; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Selected home care and medicine-contact coordination; fixed schedules excluded. |
| NHSBT rejection explanation and surveillance; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Immune rejection and surveillance; rates/schedules excluded. |
| NHSBT selected transplant-medicine roles and cautions; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Selected lifelong medicine roles and adverse-effect monitoring. Source fathering/mycophenolate switch wording, universal statin and antibiotic-duration rules are not adopted. |
| NHSBT transplant warning signs; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Transplant symptom contact context; reassurance excluded. |
| NHSBT selected long-term complication context; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Selected infection, kidney/metabolic/bone/cancer complication context. |
| NHSBT cardiac allograft vasculopathy explanation; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Donor-heart coronary disease and assessment; numeric/statin guarantees excluded. |
| NHSBT selected ongoing lifestyle and prevention context; clinical date unclosed | Separate NHS Blood and Transplant institution; see its own2025–26 audited financial routes. Exact clinical-page allocation, named contributors, BTS editorial payments and original drug/device-trial funding remain unclosed. National NHS website finances/policy do not substitute for NHSBT provenance. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 2 provider/professional-partner education, provisional; original trial and contributor finance unclassified. | C provisional — actual original body read, clinical review date unclosed. Specialist/public-care accountability supports checking; transplant-service priorities, simplification and financially unclosed underlying trials remain. NHSBT identifies BTS collaboration; BTS official indexed disclosures show relevant commercial-sponsor routes but direct access and the complete ledger were unavailable. Selected attributed education only; numeric benefit/risk rates, fixed schedules and manufacturer efficacy excluded. Role: Selected rehabilitation, food-safety and prevention care. |
| NHLBI selected VAD framework, March24,2022; dated device wording | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual dated original body read. Public educational accuracy incentive; dated device/approval menu, simplified surgery and full author/device-trial funding gaps remain. Selected definitions, purpose and broad harm categories only; abdominal implant placement, fixed stay/survival rates and current device-market completeness excluded. Role: Selected mechanical-pump purpose and broad complication categories. |
| NHLBI total artificial heart definition, April12,2023; dated approval menu excluded | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual dated original body read. Public educational accuracy incentive; dated device/approval menu, simplified surgery and full author/device-trial funding gaps remain. Selected definitions, purpose and broad harm categories only; abdominal implant placement, fixed stay/survival rates and current device-market completeness excluded. Role: Distinction between VAD and total artificial heart. |
| Royal Papworth actual24-page LVAD patient guide, March2025 version1 | Separate Royal Papworth NHS Foundation Trust; actual2024–25 accounts notes2–3 identify public commissioners, private patients, research/education and charitable income; research strategy includes industry collaboration. actual report index says2025–26 annual report will be published shortly. Leaflet/device-supplier payments, full donors and author/trial chains unclosed. | United Kingdom; actual provider and leaflet address Papworth Road, Cambridge Biomedical Campus, Cambridge, England. Local UK service pathway, not worldwide coverage. | Tier 2 provider clinical education, provisional; original trial/device-supply finance unclassified. | C provisional — actual March2025 version1 guide selected definition, care/training and harm sections read. Specialist-care accuracy incentive, procedure/service and device-related interests; original contributor/supplier finances unresolved. Device diagrams/outcome promises, exact schedules, branded home monitors and personal anticoagulation or controller procedures excluded. Role: Selected device training, care and complication context; rates/regimens excluded. |
| Royal Papworth actual audited2024–25 accounts; dated reporting period | Separate Royal Papworth NHS Foundation Trust; actual2024–25 accounts notes2–3 identify public commissioners, private patients, research/education and charitable income; research strategy includes industry collaboration. actual report index says2025–26 annual report will be published shortly. Leaflet/device-supplier payments, full donors and author/trial chains unclosed. | United Kingdom; actual provider and leaflet address Papworth Road, Cambridge Biomedical Campus, Cambridge, England. Local UK service pathway, not worldwide coverage. | Tier 3 audited institutional financial/contact self-disclosure. | B provisional for actual dated accounts/index and Cambridge institutional address; separate2025–26 ledger not linked yet. Source self-report, dated financial period and complete page/backer allocations remain. Provenance only. |
| Royal Papworth actual report index;2025–26 annual report not yet linked | Separate Royal Papworth NHS Foundation Trust; actual2024–25 accounts notes2–3 identify public commissioners, private patients, research/education and charitable income; research strategy includes industry collaboration. actual report index says2025–26 annual report will be published shortly. Leaflet/device-supplier payments, full donors and author/trial chains unclosed. | United Kingdom; actual provider and leaflet address Papworth Road, Cambridge Biomedical Campus, Cambridge, England. Local UK service pathway, not worldwide coverage. | Tier 3 audited institutional financial/contact self-disclosure. | B provisional for actual dated accounts/index and Cambridge institutional address; separate2025–26 ledger not linked yet. Source self-report, dated financial period and complete page/backer allocations remain. Provenance only. |
| NHSBT actual audited2025–26 annual report and accounts, July2026 | Own actual140-page2025–26 accounts, printedpp108–110/121: service fees, DHSC/devolved public finance, research/trial contracts mainly universities/commercial entities and non-NHS income. Organ-transplant DHSC grant-in-aid goes to General Fund/equity, not operating income. Charity/corporate partnerships are acknowledged. Exact page and full contributor/backer chains unclosed. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 3 institutional audited financial/contact self-disclosure. | B provisional for actual financial notes and head-office contact, separately from clinical independence. Statutory audit and scrutiny support accuracy; institution self-report, incomplete allocation and author/trial chains remain. Financial provenance only. |
| NHSBT actual Bristol head-office contact | Own actual140-page2025–26 accounts, printedpp108–110/121: service fees, DHSC/devolved public finance, research/trial contracts mainly universities/commercial entities and non-NHS income. Organ-transplant DHSC grant-in-aid goes to General Fund/equity, not operating income. Charity/corporate partnerships are acknowledged. Exact page and full contributor/backer chains unclosed. | United Kingdom; NHSBT actual head office Filton, Bristol, England. UK organ-transplant remit; local allocation/coverage and individual transplant-centre pathways differ. | Tier 3 institutional audited financial/contact self-disclosure. | B provisional for actual financial notes and head-office contact, separately from clinical independence. Statutory audit and scrutiny support accuracy; institution self-report, incomplete allocation and author/trial chains remain. Financial provenance only. |
| BTS official2026 corporate scheme, indexed original; direct access failed | Official indexed2026 corporate scheme lists paid sponsorship, additional congress symposia and sponsored fellowships; official indexed partner list includes Astellas, Chiesi and other relevant pharmaceutical/device businesses. Direct originals returned403; ordinary public fetch failed DNS. Complete audited income, named contributor interests and page-specific allocation were not retrieved; no sponsorship of a particular NHSBT page is inferred. | United Kingdom professional society; complete current legal headquarters, sponsor corporate chains and manufacturing jurisdictions not cleared in this focused audit. | Tier 3 society financial/partner self-disclosure, access-limited; sponsor-origin product promotion Tier4/D excluded. | C provisional for attributed indexed-original funding context, explicitly not full-page access or clean clinical independence. Sponsor visibility and professional education interests remain; no efficacy, product testimonial or precise sponsorship amount adopted. Role: Official indexed sponsor-route context; direct full-page access failed. |
| BTS official2026 partner listing, indexed original; direct access failed | Official indexed2026 corporate scheme lists paid sponsorship, additional congress symposia and sponsored fellowships; official indexed partner list includes Astellas, Chiesi and other relevant pharmaceutical/device businesses. Direct originals returned403; ordinary public fetch failed DNS. Complete audited income, named contributor interests and page-specific allocation were not retrieved; no sponsorship of a particular NHSBT page is inferred. | United Kingdom professional society; complete current legal headquarters, sponsor corporate chains and manufacturing jurisdictions not cleared in this focused audit. | Tier 3 society financial/partner self-disclosure, access-limited; sponsor-origin product promotion Tier4/D excluded. | C provisional for attributed indexed-original funding context, explicitly not full-page access or clean clinical independence. Sponsor visibility and professional education interests remain; no efficacy, product testimonial or precise sponsorship amount adopted. Role: Official indexed relevant partner examples; full financial chain unclosed. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
Frequently asked questions
Is an LVAD the same as a transplant? No; it mechanically assists circulation.
Does being on the list guarantee a donor heart soon? No; matching, availability and health status matter.
Can rejection occur without obvious symptoms? Yes; surveillance can detect changes before symptoms.
Can I stop anti-rejection medicine when I feel well? Do not stop it without the transplant team.
Is every pump used only until transplantation? The intended support strategy varies.
Can a website teach me to change a controller or pump setting? Use training and instructions from the actual device team.
Sources and funding notes
- NHSBT heart-transplant overview and BTS collaboration; clinical date unclosed — Transplant definition and explicitly stated BTS clinical partnership.
- NHSBT selected transplant assessment tests; clinical date unclosed — Selected whole-person and compatibility assessment.
- NHSBT reasons transplantation may not suit; clinical date unclosed — Suitability, reassessment and advanced-care alternatives.
- NHSBT waiting-list and matching explanation; clinical date unclosed — UK matching, contact and ongoing review; fixed timings excluded.
- NHSBT donated-heart risk discussion; clinical date unclosed — Specific donor-risk consent and residual screening uncertainty.
- NHSBT selected hospital recovery and discharge planning; clinical date unclosed — Critical-care recovery, discharge and support preparation.
- NHSBT selected care at home after transplantation; clinical date unclosed — Selected home care and medicine-contact coordination; fixed schedules excluded.
- NHSBT rejection explanation and surveillance; clinical date unclosed — Immune rejection and surveillance; rates/schedules excluded.
- NHSBT selected transplant-medicine roles and cautions; clinical date unclosed — Selected lifelong medicine roles and adverse-effect monitoring.
- NHSBT transplant warning signs; clinical date unclosed — Transplant symptom contact context; reassurance excluded.
- NHSBT selected long-term complication context; clinical date unclosed — Selected infection, kidney/metabolic/bone/cancer complication context.
- NHSBT cardiac allograft vasculopathy explanation; clinical date unclosed — Donor-heart coronary disease and assessment; numeric/statin guarantees excluded.
- NHSBT selected ongoing lifestyle and prevention context; clinical date unclosed — Selected rehabilitation, food-safety and prevention care.
- NHLBI selected VAD framework, March24,2022; dated device wording — Selected mechanical-pump purpose and broad complication categories.
- NHLBI total artificial heart definition, April12,2023; dated approval menu excluded — Distinction between VAD and total artificial heart.
- Royal Papworth actual24-page LVAD patient guide, March2025 version1 — Selected device training, care and complication context; rates/regimens excluded.
- Royal Papworth actual audited2024–25 accounts; dated reporting period — Actual own-provider dated financial provenance.
- Royal Papworth actual report index;2025–26 annual report not yet linked — Current availability of own financial report and Cambridge address.
- NHSBT actual audited2025–26 annual report and accounts, July2026 — Actually opened own-provider financial provenance.
- NHSBT actual Bristol head-office contact — Actually opened Bristol head-office provenance.
- BTS official2026 corporate scheme, indexed original; direct access failed — Official indexed sponsor-route context; direct full-page access failed.
- BTS official2026 partner listing, indexed original; direct access failed — Official indexed relevant partner examples; full financial chain unclosed.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
The clinical originals and NHSBT, Royal Papworth and NHLBI financial sources were opened; BTS finance is explicitly access-limited. Actual NHSBT overview, tests, suitability, waiting, donor risk, hospital recovery/home care, rejection, medicines, warnings, long-term complications, CAV and healthy-living originals read; clinical review dates unclosed. Fixed survival/risk/recovery/testing schedules, current UK long-term-pump coverage, universal statin/antimicrobial rules, outdated fathering/mycophenolate switch instruction and reassurance that infections/rejection are usually minor excluded. Actual own140-page2025–26 accounts selected financial notes and Bristol contact read. BTS official indexed2026 corporate scheme/partners reviewed for financial context; direct403 and public-fetch DNS failures mean no full-page/ledger or author clearance. Actual NHLBI March24,2022 device framework andApril12,2023TAH original read; dated implant placement, current approval/menu, fixed hospital/survival claims excluded. Actual Royal Papworth March2025 version1 guide selected definition/training/care/harms and2024–25 accounts notes2–3/industry strategy plus current annual-report index read;2025–26 annual report not yet linked. Patient outcomes, numeric harm rates, fixed recovery/driving/showering/dressing/clinic schedules, UK pump-coverage assertion, personal anticoagulation and controller procedures excluded. Full2026ESC HF original remained inaccessible; no exact current eligibility criterion inferred from summaries. This is selected attributed clinical education, not complete independent drug/device outcome appraisal. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.